Sartorius Stedim Biotech to Acquire Albumedix for £415m | Photo credits: Sartorius Stedim
PARIS (Agefi-Dow Jones)– Pharmaceutical industry supplier Sartorius Stedim Biotech said on Monday it would acquire 100% of British company Albumedix from private investors for nearly £415 million. (about 492 million euros). Based in Nottingham and established in 1984, Albumedix “has over 100 employees and is expected to achieve sales of around £33m in 2022 with a strong EBITDA margin. [excédent brut d’exploitation,ndlr] double digits,” said Sartorius Stedim Biotech.
The group specifies that Albumedix is specialized in recombinant human albumin which constitutes “a critical component in the manufacture of innovative biopharmaceutical products, in particular for modalities such as cell or viral therapies and vaccines”.
Subject to regulatory approvals, Sartorius Stedim Biotech expects the transaction to close before the end of the third quarter of 2022.
-Vincent Alsuar, Agefi-Dow Jones; 01 41 27 47 39; [email protected] ed: FXS
Agefi-Dow Jones The financial newswire
Dow Jones Newswires
August 08, 2022 12:57 ET (16:57 GMT)